Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate

Folia Pharmacologica Japonica

Volumn 122, Issue 2, 2003, Pages 161-178

  Minami, Shinzaburo ^a   Hattori, Rikizou ^a   Matsuda, Akira ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

DNA gyrase; Injectable quinolone; Pazufloxacin mesilate; Resistance; Topoisomerase

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; CEFAZOLIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; DNA TOPOISOMERASE INHIBITOR; DNA TOPOISOMERASE IV; ENOXACIN; ERYTHROMYCIN; FLEROXACIN; GENTAMICIN; GYRASE INHIBITOR; LEVOFLOXACIN; LOMEFLOXACIN; MEROPENEM; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PANIPENEM PLUS BETAMIPRON; PAZUFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEICOPLANIN; TEMAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ADNEXITIS; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BILIARY TRACT INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DRUG EFFICACY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONITIS; POSTANTIBIOTIC EFFECT; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SURGICAL INFECTION; TOXICITY TESTING; URINARY TRACT INFECTION;

4-QUINOLONES; ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; CAPILLARY PERMEABILITY; DNA GYRASE; DNA REPLICATION; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HEMODYNAMIC PROCESSES; HISTAMINE RELEASE; HUMANS; INFUSIONS, INTRAVENOUS; OXAZINES; SEIZURES;

EID: 0042155803     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.122.161     Document Type: Review

References (22)

1. Davis RL, Kalman D, Marchbanks CR. Intravenous ciprofloxacin: a position statement by the society of infectious diseases pharmacists. Ann Pharmacother. 1993;27:362-364.
2. Leroy O, Beuscart C, Chidiac C, Beaucaire G, Sivery B, Mouton Y. First Experience of Ofloxacin IV: 273 Patients in a French Multicentric Study, Program and Abstracts of the Twenty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy (California), Abs.383, 1988
3. Arcieri GM, Becker N, Esposito B, et al. Safety of intravenous ciprofloxacin. Am J Med. 1989;87 Suppl 5A:92S-97S.
4. Chemotherapy. 1964;12(3):176-179.
5. Medicina. 1999;36(1):18-25.
6. Chemotherapy. 1990;38(4):363-370.